Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
Revolution Medicines (Nasdaq: RVMD) will report first-quarter 2026 financial results on May 6, 2026 after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Revolution Medicines (Nasdaq: RVMD) will report first-quarter 2026 financial results on May 6, 2026 after market close. A live webcast with senior management will begin at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and corporate progress.
The live webcast and an archived replay (available for at least 14 days) can be accessed via the company's investor events and presentations page.
Details
News Market Reaction – RVMD
On Apr 30, the first trading day after this news, RVMD closed 2.54% above the previous close.
Data tracked by StockTitan Argus for the Apr 30 session.
Key Figures
- Q1 2026 report date
- May 6, 2026
- Scheduled financial results release after market close
- Earnings webcast time
- 4:30 p.m. ET
- Start time for Q1 2026 results webcast
- Replay availability
- 14 days
- Webcast replay duration on company website
Previous Earnings date Reports
-
Scheduled Q4 and full-year 2025 results with webcast and replay details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.